{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T16:02:38Z","timestamp":1789574558529,"version":"build-2803163510"},"reference-count":47,"publisher":"American Medical Association (AMA)","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"abstract":"\n Importance<\/jats:title>\n Limited data are available on the long-term effectiveness and safety of dupilumab in pediatric patients with atopic dermatitis (AD) in a clinical setting.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To assess the clinical effectiveness, safety, drug survival, and reasons and associated factors for discontinuation of dupilumab across pediatric age groups with up to 3 years of follow-up.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This multicenter, prospective cohort study (BioDay Registry) was conducted across 4 academic and 3 nonacademic hospitals in the Netherlands from November 2019 to October 2025 and included pediatric patients (\u226416 years) with moderate to severe AD who initiated treatment with dupilumab. Data were analyzed from September 2025 to January 2026.<\/jats:p>\n <\/jats:sec>\n \n Exposure(s)<\/jats:title>\n Dupilumab was administered at the label-recommended dose. Dose reduction was initiated if clinically indicated.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Clinical effectiveness was evaluated by the Eczema Area and Severity Index (EASI) and Investigator Global Assessment (IGA). Additional outcomes included the Numeric Rating Scale (NRS) for pruritus, NRS for pain, and quality of life (QoL) scores. Safety was assessed by adverse events (AEs). Drug survival, reasons, and factors associated with discontinuation were evaluated.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Overall, 309 pediatric patients with AD (mean [SD] age, 10.2 [4.2] years; 150 female individuals [48.5%] and 159 male individuals [51.5%]) were treated with dupilumab; 51 (16.5%) were aged 6 months to 5 years (median follow-up, 45.0 [IQR, 26.0-101.0] weeks), 120 (38.8%) were aged 6 to 11 years (median follow-up, 80.0 [IQR, 32.0-135.0] weeks), and 138 (44.7%) were aged 12 to 16 years (median follow-up, 89.5 [IQR, 48.0-143.0] weeks) at baseline. Most patients maintained controlled AD, with mean EASI and NRS scores for pruritus remaining low after 3 years (3.4 [95% CI, 2.4-4.5] and 3.6 [95% CI, 3.1-4.1], respectively). Age groups differed significantly in NRS for pruritus and QoL scores over time, with children aged 6 months to 5 years consistently reporting higher scores than older children. The most frequently reported AE was dupilumab-associated ocular surface disease (113 [36.6%]). Fifty patients (50 [16.2%]) discontinued dupilumab, mainly due to ineffectiveness (19 [38.0%]) and\/or AEs (15 [30.0%]), or administration problems (11 [22.0%]); most discontinuations occurred within 1.5 years. Three-year drug survival was 80.1%; allergic asthma, allergic rhinitis, and being age 6 to 11 years were associated with a lower risk of discontinuation.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n The results of this cohort study suggest that dupilumab demonstrates long-term effectiveness and safety in pediatric AD in a clinical setting. Younger children show higher NRS scores for pruritus and greater QoL impairment and discontinue treatment more often due to administration problems, highlighting age-specific challenges.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamadermatol.2026.3548","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T15:03:25Z","timestamp":1789571005000},"source":"Crossref","is-referenced-by-count":0,"title":["Long-Term Effectiveness, Safety, and Survival of Dupilumab in Pediatric Atopic Dermatitis"],"prefix":"10.1001","author":[{"given":"Florence","family":"Vroman","sequence":"first","affiliation":[{"name":"Department of Dermatology, University Medical Center Utrecht, University of Utrecht, Utrecht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Octavian I.","family":"Baco\u015f-Cosma","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Loman","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolaas P. A.","family":"Zuithoff","sequence":"additional","affiliation":[{"name":"Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marijke","family":"Kamsteeg","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Radboud University Medical Center, Nijmegen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Moon","family":"van Tuyll van Serooskerken","sequence":"additional","affiliation":[{"name":"Department of Dermatology, HagaZiekenhuis and Juliana Pediatric Hospital, The Hague, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula P. M.","family":"van L\u00fcmig","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Maastricht University Medical Centre, Maastricht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert J.","family":"Oosting","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Spaarne Gasthuis, Hoofddorp, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Hendriks","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Catharina Hospital, Eindhoven, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjolein S.","family":"de Bruin-Weller","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Medical Center Utrecht, University of Utrecht, Utrecht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Louise A.","family":"Schuttelaar","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlies","family":"de Graaf","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Medical Center Utrecht, University of Utrecht, Utrecht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,9,16]]},"reference":[{"issue":"10247","key":"doi260042r1","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/S0140-6736(20)31286-1","article-title":"Atopic dermatitis.","volume":"396","author":"Langan","year":"2020","journal-title":"Lancet"},{"issue":"11","key":"doi260042r2","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.3346\/jkms.2012.27.11.1327","article-title":"Quality of life and disease severity are correlated in patients with atopic dermatitis.","volume":"27","author":"Kim","year":"2012","journal-title":"J Korean Med Sci"},{"issue":"12","key":"doi260042r3","doi-asserted-by":"publisher","first-page":"2717","DOI":"10.1111\/jdv.16892","article-title":"ETFAD\/EADV eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children.","volume":"34","author":"Wollenberg","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"9","key":"doi260042r4","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1111\/jdv.20639","article-title":"European guideline (EuroGuiDerm) on atopic eczema: Living update.","volume":"39","author":"Wollenberg","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"doi260042r6","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1007\/s40257-024-00859-y","article-title":"Dupilumab safety and efficacy up to 1 year in children aged 6 months to 5 years with atopic dermatitis: results from a phase 3 open-label extension study.","volume":"25","author":"Paller","year":"2024","journal-title":"Am J Clin Dermatol"},{"issue":"11","key":"doi260042r7","doi-asserted-by":"publisher","first-page":"2697","DOI":"10.1007\/s13555-023-01016-9","article-title":"Dupilumab safety and efficacy in a phase III open-label extension trial in children 6-11 years of age with severe atopic dermatitis.","volume":"13","author":"Cork","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"3","key":"doi260042r8","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s40257-022-00683-2","article-title":"Long-term efficacy and safety of dupilumab in adolescents with moderate-to-severe atopic dermatitis: results through week 52 from a phase III open-label extension trial (LIBERTY AD PED-OLE).","volume":"23","author":"Blauvelt","year":"2022","journal-title":"Am J Clin Dermatol"},{"issue":"10","key":"doi260042r9","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1001\/jamadermatol.2024.2517","article-title":"Long-term effectiveness and reasons for discontinuation of dupilumab in patients with atopic dermatitis.","volume":"160","author":"Boesjes","year":"2024","journal-title":"JAMA Dermatol"},{"issue":"12","key":"doi260042r10","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1111\/jdv.18450","article-title":"Effectiveness and safety of dupilumab in the treatment of atopic dermatitis in children (6-11?years): data from a French multicentre retrospective cohort in daily practice.","volume":"36","author":"Lasek","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"doi260042r11","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1007\/s40257-025-00962-8","article-title":"Systemic treatments in moderate-to-severe atopic dermatitis in pediatric patients up to 12 years of age: real-world treatment outcomes from the PEDISTAD Registry.","volume":"26","author":"Paller","year":"2025","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"doi260042r12","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/ajd.70031","article-title":"A real-world retrospective cohort study on the use of dupilumab for severe atopic dermatitis in patients aged 6 months to 16?years.","volume":"67","author":"Wheller","year":"2026","journal-title":"Australas J Dermatol"},{"key":"doi260042r13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1644875","article-title":"Effectiveness and safety of dupilumab in the treatment of pediatric atopic dermatitis: a real-world study from China.","volume":"16","author":"Xu","year":"2025","journal-title":"Front Immunol"},{"issue":"1","key":"doi260042r14","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2025.2460578","article-title":"Real-world efficacy and safety of dupilumab in children with atopic dermatitis under 6 years of age: a retrospective multicentric study.","volume":"36","author":"Rob","year":"2025","journal-title":"J Dermatolog Treat"},{"issue":"1","key":"doi260042r15","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1093\/ced\/llae300","article-title":"Dupilumab treatment in paediatric atopic dermatitis (2-18?years): Spanish multicentre retrospective real-world study.","volume":"50","author":"Iznardo","year":"2024","journal-title":"Clin Exp Dermatol"},{"issue":"6","key":"doi260042r16","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1093\/ced\/llae013","article-title":"Real-world outcomes of children treated with dupilumab for moderate-to-severe atopic dermatitis: a single-centre retrospective observational UK study.","volume":"49","author":"Hosseini-Ashrafi","year":"2024","journal-title":"Clin Exp Dermatol"},{"issue":"2","key":"doi260042r17","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1159\/000535282","article-title":"Effectiveness and safety of dupilumab in children under 6 years of age with moderate-to-severe atopic dermatitis: a retrospective real-world study.","volume":"240","author":"Berna-Rico","year":"2024","journal-title":"Dermatology"},{"issue":"1","key":"doi260042r18","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2023.2246602","article-title":"A 52-week multicenter retrospective real-world study on effectiveness and safety of dupilumab in children with atopic dermatitis aged from 6 to 11 years.","volume":"34","author":"Patruno","year":"2023","journal-title":"J Dermatolog Treat"},{"issue":"1","key":"doi260042r19","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/pde.15418","article-title":"Multicenter Canadian case series of pediatric patients less than 12?years of age with moderate-to-severe atopic dermatitis treated with dupilumab.","volume":"41","author":"Martinez-Cabriales","year":"2024","journal-title":"Pediatr Dermatol"},{"issue":"8","key":"doi260042r20","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1111\/jdv.18141","article-title":"Moderate-to-severe atopic dermatitis in adolescents treated with dupilumab: a multicentre Italian real-world experience.","volume":"36","author":"Stingeni","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"9","key":"doi260042r21","doi-asserted-by":"publisher","first-page":"2378","DOI":"10.1016\/j.jaip.2022.06.014","article-title":"Dupilumab improves clinical scores in children and adolescents with moderate to severe atopic dermatitis: a real-world, single-center study.","volume":"10","author":"Pagan","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"12","key":"doi260042r22","doi-asserted-by":"publisher","DOI":"10.1111\/pai.13887","article-title":"Dupilumab in daily practice for the treatment of pediatric atopic dermatitis: 28-week clinical and biomarker results from the BioDay registry.","volume":"33","author":"Kamphuis","year":"2022","journal-title":"Pediatr Allergy Immunol"},{"issue":"6","key":"doi260042r23","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/s40272-022-00531-0","article-title":"Dupilumab treatment in children aged 6-11 years with atopic dermatitis: a multicentre, real-life study.","volume":"24","author":"Napolitano","year":"2022","journal-title":"Paediatr Drugs"},{"issue":"2","key":"doi260042r24","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1093\/ced\/llae406","article-title":"Real-world efficacy and safety of dupilumab for paediatric atopic dermatitis: a multicentre retrospective study.","volume":"50","author":"Pirov","year":"2025","journal-title":"Clin Exp Dermatol"},{"issue":"4","key":"doi260042r27","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1111\/pde.15003","article-title":"Validation of remote atopic dermatitis severity assessment with the Eczema Area and Severity Ondex in children using caregiver-provided photos and videos.","volume":"39","author":"Croce","year":"2022","journal-title":"Pediatr Dermatol"},{"issue":"2","key":"doi260042r28","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.jaad.2023.08.104","article-title":"Development and validation of a caregiver-reported Numeric Rating Scale for measuring worst scratch\/itch in patients aged 6 months to younger than 6 years with atopic dermatitis.","volume":"90","author":"Paller","year":"2024","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"doi260042r29","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1111\/j.1365-2133.1995.tb16953.x","article-title":"The Children\u2019s Dermatology Life Quality Index (CDLQI): initial validation and practical use.","volume":"132","author":"Lewis-Jones","year":"1995","journal-title":"Br J Dermatol"},{"issue":"2","key":"doi260042r30","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.jaad.2015.09.062","article-title":"A systematic review of Investigator Global Assessment (IGA) in atopic dermatitis (AD) trials: many options, no standards.","volume":"74","author":"Futamura","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"doi260042r31","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1111\/j.1365-2222.2006.02430.x","article-title":"Increased serum thymus and activation-regulated chemokine and cutaneous T cell-attracting chemokine levels in children with atopic dermatitis.","volume":"36","author":"Song","year":"2006","journal-title":"Clin Exp Allergy"},{"issue":"2","key":"doi260042r32","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","article-title":"The medical dictionary for regulatory activities (MedDRA).","volume":"20","author":"Brown","year":"1999","journal-title":"Drug Saf"},{"issue":"1","key":"doi260042r34","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/biomet\/80.1.27","article-title":"Bias reduction of maximum likelihood estimates.","volume":"80","author":"Firth","year":"1993","journal-title":"Biometrika"},{"issue":"5","key":"doi260042r35","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1111\/bjd.19460","article-title":"Dupilumab provides favourable long-term safety and efficacy in children aged = 6 to < 12 years with uncontrolled severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension study.","volume":"184","author":"Cork","year":"2021","journal-title":"Br J Dermatol"},{"issue":"3","key":"doi260042r36","doi-asserted-by":"publisher","DOI":"10.1111\/jspn.12316","article-title":"Comparison of child self-report and parent proxy-report of symptoms: Results from a longitudinal symptom assessment study of children with advanced cancer.","volume":"26","author":"Montgomery","year":"2021","journal-title":"J Spec Pediatr Nurs"},{"issue":"10","key":"doi260042r37","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1007\/s00431-013-2049-9","article-title":"Health-related quality of life and symptom reporting: similarities and differences between children and their parents.","volume":"172","author":"Eiser","year":"2013","journal-title":"Eur J Pediatr"},{"issue":"1","key":"doi260042r38","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jaci.2024.08.005","article-title":"Dupilumab reduces inflammatory biomarkers in pediatric patients with moderate-to-severe atopic dermatitis.","volume":"155","author":"Beck","year":"2025","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"doi260042r39","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1111\/all.70090","article-title":"Dupilumab in children under 6 years with moderate-to-severe atopic dermatitis: a 16-week real-world prospective study on efficacy, safety, and local-systemic immune responses.","volume":"81","author":"Zhang","year":"2026","journal-title":"Allergy"},{"issue":"5","key":"doi260042r40","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1111\/cea.70025","article-title":"Dupilumab-associated ocular surface disease in paediatric atopic dermatitis patients: results from the BioDay Registry.","volume":"55","author":"van der Rijst","year":"2025","journal-title":"Clin Exp Allergy"},{"issue":"1","key":"doi260042r41","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1001\/jamadermatol.2024.3717","article-title":"Drug survival of dupilumab, methotrexate, and cyclosporine A in children with atopic dermatitis.","volume":"161","author":"van der Rijst","year":"2025","journal-title":"JAMA Dermatol"},{"issue":"5","key":"doi260042r42","doi-asserted-by":"publisher","DOI":"10.1002\/ski2.413","article-title":"Atopic dermatitis in 32 children treated with dupilumab in real life: a new contribution.","volume":"4","author":"Betlloch-Mas","year":"2024","journal-title":"Skin Health Dis"},{"key":"doi260042r43","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2025.108486","article-title":"The impact of early experiences of needle procedures on the lives of people living with cystic fibrosis: a qualitative and quantitative exploration.","volume":"249","author":"Stephenson","year":"2025","journal-title":"Respir Med"},{"issue":"1","key":"doi260042r44","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s12969-020-0406-6","article-title":"Children\u2019s fear of needle injections: a qualitative study of training sessions for children with rheumatic diseases before home administration.","volume":"18","author":"S\u00f8rensen","year":"2020","journal-title":"Pediatr Rheumatol Online J"},{"issue":"1","key":"doi260042r45","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s00431-018-3286-8","article-title":"The effect of repeated methotrexate injections on the quality of life of children with rheumatic diseases.","volume":"178","author":"Jacobse","year":"2019","journal-title":"Eur J Pediatr"},{"issue":"1","key":"doi260042r46","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2023.2254567","article-title":"Biologicals for pediatric patients with atopic dermatitis: practical challenges and knowledge gaps.","volume":"34","author":"van der Rijst","year":"2023","journal-title":"J Dermatolog Treat"},{"key":"doi260042r47","article-title":"[Procedural comfort care in pediatric healthcare: bringing children from fear to trust].","volume":"170","author":"Leroy","year":"2026","journal-title":"Ned Tijdschr Geneeskd"},{"key":"doi260042r5","unstructured":"European Medicines Agency. Dupixent (dupilumab): an overview of Dupixent and why it is authorised in the EU. Accessed July 3, 2025. https:\/\/www.ema.europa.eu\/en\/documents\/overview\/dupixent-epar-medicine-overview_en.pdf"},{"key":"doi260042r25","unstructured":"European Medicines Agency. Dupixent (dupilumab): summary of product characteristics. Accessed July 3, 2025. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/dupixent-epar-product-information_en.pdf"},{"key":"doi260042r26","doi-asserted-by":"crossref","unstructured":"Vroman? F, Bacos-Cosma? OI, de Krosse? LC, . Successful dose reduction of dupilumab in pediatric patients with atopic dermatitis in daily practice: results from the BioDay registry. Expert Opinion on Biological Therapy. Published online July 15, 2026. doi:10.1080\/14712598.2026.2703825","DOI":"10.1080\/14712598.2026.2703825"},{"key":"doi260042r33","unstructured":"US Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE). Accessed October 7, 2026, https:\/\/dctd.cancer.gov\/research\/ctep-trials\/for-sites\/adverse-events\/ctcae-v5-5x7.pdf"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2853814\/jamadermatology_vroman_2026_oi_260042_1788201844.02651.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T15:03:27Z","timestamp":1789571007000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2853814"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,16]]},"references-count":47,"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2026.3548","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,16]]}}}